13F-HR filed by BVF INC/IL
BVF INC/IL filed this 13F-HR for the quarter ended 2017-12-31, filed 2018-02-14, with 43 holding rows worth $829,549,000.
- Accession
- 0000921895-18-000676
- Filer
- CIK 1056807
- Filed
- 2018-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2017
A holdings report, 43 entries on the cover page, a total value of $829,549,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $829,549,000 with VALUE read as thousands by filing date, 13F file number 028-06800. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerBVF PARTNERS L P/IL028-06770
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ARRAY BIOPHARMA INC COM | 04269X105 | Stock | 8,686,498 | $111,187,000 | thousands by filing date | |
| ANAPTYSBIO INC | 032724106 | COM | 594,397 | $59,868,000 | thousands by filing date | |
| BLUEPRINT MEDICINES CORP | 09627Y109 | COM | 767,354 | $57,866,000 | thousands by filing date | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 1,502,800 | $53,500,000 | thousands by filing date | |
| CONCERT PHARMACEUTICALS INC | 206022105 | COM | 1,969,789 | $50,958,000 | thousands by filing date | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 5,721,888 | $46,633,000 | thousands by filing date | |
| CHEMOCENTRYX INC | 16383L106 | COM | 7,587,416 | $45,145,000 | thousands by filing date | |
| BIOLINERX LTD-SPONS ADR | 09071M106 | SPON | 25,995,575 | $28,335,000 | thousands by filing date | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 3,233,618 | $28,326,000 | thousands by filing date | |
| ARQULE INC | 04269E107 | COM | 16,436,912 | $27,121,000 | thousands by filing date | |
| CYTOMX THERAPEUTICS INC | 23284F105 | COMMON STOCK | 1,124,483 | $23,738,000 | thousands by filing date | |
| CTI BIOPHARMA CORP | 12648L601 | COM | 8,596,357 | $23,038,000 | thousands by filing date | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 1,353,846 | $20,714,000 | thousands by filing date | |
| INFINITY PHARMACEUTICALS INC | 45665G303 | COM | 9,766,508 | $19,826,000 | thousands by filing date | |
| PIERIS PHARMACEUTICALS INC | 720795103 | COM | 2,623,562 | $19,808,000 | thousands by filing date | |
| ONCOMED PHARMACEUTICALS INC COM | 68234X102 | Stock | 4,271,289 | $17,512,000 | thousands by filing date | |
| REGULUS THERAPEUTICS INC | 75915K101 | COM | 13,974,249 | $14,533,000 | thousands by filing date | |
| GTX INC DEL | 40052B207 | COM NEW | 1,107,433 | $14,075,000 | thousands by filing date | |
| PHAXIAM THERAPEUTICS S A | 29604W108 | SPONSORED ADR | 625,000 | $13,763,000 | thousands by filing date | |
| VBI VACCINES INC | 91822J103 | COM NEW | 3,100,000 | $13,237,000 | thousands by filing date | |
| FORWARD PHARMA A/S | 34986J105 | SPONSORED ADR | 3,455,117 | $12,646,000 | thousands by filing date | |
| SPERO THERAPEUTICS INC | 84833T103 | COM | 1,029,185 | $12,093,000 | thousands by filing date | |
| CASCADIAN THERAPEUTICS INC | 14740B606 | COM NEW | 3,133,224 | $11,593,000 | thousands by filing date | |
| SPRING BK PHARMACEUTICALS IN | 849431101 | COM | 823,474 | $11,076,000 | thousands by filing date | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 3,588,830 | $10,138,000 | thousands by filing date | |
| GLYCOMIMETICS INC | 38000Q102 | COM | 497,474 | $8,353,000 | thousands by filing date | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 675,759 | $7,569,000 | thousands by filing date | |
| SUNESIS PHARMACEUTICALS INC | 867328700 | COM | 2,043,196 | $7,539,000 | thousands by filing date | |
| MOLECULAR TEMPLATES INC | 608550109 | COM | 724,132 | $7,256,000 | thousands by filing date | |
| VERASTEM INC | 92337C104 | COM | 2,250,000 | $6,908,000 | thousands by filing date | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 294,117 | $6,118,000 | thousands by filing date | |
| IMMUNE DESIGN CORP. | 45252L103 | Common Stock | 1,469,800 | $5,732,000 | thousands by filing date | |
| TOCAGEN INC | 888846102 | COM | 556,683 | $5,706,000 | thousands by filing date | |
| CORVUS PHARMACEUTICALS INC | 221015100 | COM | 459,396 | $4,759,000 | thousands by filing date | |
| ACHILLION PHARMACEUTICALS IN | 00448Q201 | COM | 1,608,433 | $4,632,000 | thousands by filing date | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 273,350 | $3,958,000 | thousands by filing date | |
| OREXIGEN THERAPEUTICS INC | 686164AB0 | NOTE 2.750%12/0 | 10,000,000 | $3,550,000 | thousands by filing date | principal |
| CONTRAFECT CORP | 212326102 | COM | 3,500,000 | $3,535,000 | thousands by filing date | |
| VICAL INC | 925602203 | COM NEW | 1,409,444 | $2,579,000 | thousands by filing date | |
| Anthera Pharmaceuticals Inc (NV) | 03674U300 | COM | 1,216,403 | $2,007,000 | thousands by filing date | |
| PAIN THERAPEUTICS INC | 69562K506 | COM NEW | 325,509 | $1,302,000 | thousands by filing date | |
| OREXIGEN THERAPEUTICS INC COM NEW | 686164302 | Stock | 734,976 | $948,000 | thousands by filing date | |
| LOXO ONCOLOGY INC | 548862101 | COM | 4,386 | $369,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000921895-18-000676 | this filing | 2018-02-14 | acceptance time not in the bulk data set |